Selective review and commentary on emerging pharmacotherapies for opioid addiction

References

• KrupitskyEMBlokhinaEALong-acting depot formulations of naltrexone for heroin dependence: a reviewCurr Opin Psychiatry201023321021420224403
   PubMed Web of Science ®Google Scholar
• GowingLAliRWhiteJBuprenorphine for the management of opioid withdrawalCochrane Database Syst Rev2006192CD00202516625553
   PubMedGoogle Scholar
• GowingLFarrellMAliRWhiteJMAlpha2-adrenergic agonists for the management of opioid withdrawalCochrane Database Syst Rev2009152CD00202419370574
   PubMed Web of Science ®Google Scholar
• GishECMillerJLHoneyBLJohnsonPNLofexidine, an {alpha}2-receptor agonist for opioid detoxificationAnn Pharmacother201044234335120040696
   PubMed Web of Science ®Google Scholar
• StrangJBearnJGossopMLofexidine for opiate detoxification: review of recent randomised and open controlled trialsAm J Addict19998433734810598217
   PubMed Web of Science ®Google Scholar
• LinSKStrangJSuLWTsaiCJHuWHDouble blind randomized controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawalDrug Alcohol Depend19974821271339363412
   PubMed Web of Science ®Google Scholar
• YuEMiottoKAkereleEA Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawalDrug Alcohol Depend2008971–215816818508207
   PubMed Web of Science ®Google Scholar
• HandelsmanLCochraneKJAronsonMJNessRRubinsteinKJKanofPDTwo new rating scales for opiate withdrawalAm J Alcohol Abuse1987133293308
   PubMed Web of Science ®Google Scholar
• WessonDRLingWThe Clinical Opiate Withdrawal Scale (COWS)J Psychoactive Drugs200335225325912924748
   PubMed Web of Science ®Google Scholar
• TompkinsDABigelowGEHarrisonJAJohnsonREFudalaPJStrainECConcurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrumentDrug Alcohol Depend20091051–215415919647958
   PubMed Web of Science ®Google Scholar
• FiellinDAO’ConnorPGNew federal initiatives to enhance the medical treatment of opioid dependenceAnn Intern Med2002137868869212379070
   PubMed Web of Science ®Google Scholar
• AmassLKamienJBMikulichSKEfficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tabletDrug Alcohol Depend2000581–214315210669065
   PubMed Web of Science ®Google Scholar
• CopenhaverMBruceRAlticeFBehavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidenceAm J Drug Alcohol Abuse200733564365417891657
   PubMed Web of Science ®Google Scholar
• FiellinDARosenheckRAKostenTROffice-based treatment for opioid dependence: reaching new patient populationsAm J Psychiatry200115881200120411481150
   PubMed Web of Science ®Google Scholar
• FudalaPJBridgeTPHerbertSChiangCNLeidermanDBThe Buprenorphine/Naloxone Collaborative Study GroupA multisite efficacy evaluation of a buprenorphine/naloxone product for opioid dependence treatmentNIDA Research Monograph 179Rockville, MDDHHS/NIH/NIDA1998
   Google Scholar
• LingWWessonDRCharuvastraCKlettCJA controlled trial comparing buprenorphine and methadone maintenance in opioid dependenceArch Gen Psychiatry19965354014078624183
   PubMed Web of Science ®Google Scholar
• LingWWessonDRClinical efficacy of buprenorphine: comparisons to methadone and placeboDrug Alcohol Depend2003702 SupplS49S5712738350
   PubMed Web of Science ®Google Scholar
• AmassLLingWFreeseTEBringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experienceAm J Addict200413Suppl 1S42S6615204675
   PubMed Web of Science ®Google Scholar
• ComptonPAWessonDRCharuvastraVCLingWBuprenorphine as a pharmacotherapy for opioid addiction. What dose provides a therapeutic response?Am J Addict19965220222
   Web of Science ®Google Scholar
• FudalaPJBridgeTPHerbertSOffice-based treatment of opioid addiction with a sublingual-tablet formulation of buprenorphine and naloxoneN Eng J Med200334910949958
   PubMed Web of Science ®Google Scholar
• SAMHSA (Substance Abuse and Mental Health Services Administration)SAMHSA/CSAT Buprenorphine Information Center2010 Available from: http://buprenorphine.samhsa.gov/faq.htmlAccessed Jul 2011
   Google Scholar
• Titan PharmaceuticalsInvestigator’s BrochureConfidential research protocol documentation6212008
   Google Scholar
• LingWCassdontePBigelowGBuprenorphine implants for treatment of opioid dependence: a randomized controlled trialJAMA2010304121576158320940383
   PubMed Web of Science ®Google Scholar
• Titan PharmaceuticalsPress Release: Titan Pharmaceuticals Announces Positive Top Line Results In Confirmatory Phase 3 Trial Of Probuphine5162011 Accessed from: http://www.titanpharm.com/press/110816-phase3-probuphine-positive-results.htmAccesed 13 September, 2011
   Google Scholar
• GonzalezJPBrogdenRNNaltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependenceDrugs19883531922132836152
   PubMed Web of Science ®Google Scholar
• GonzalezGOlivetoAKostenTRCombating opiate dependence: a comparison among the available pharmacological optionsExpert Opin Pharmacother20045471372515102558
   PubMed Web of Science ®Google Scholar
• JudsonBACarneyTMGoldsteinANaltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparisonDrug Alcohol Depend1981743253467023894
   PubMed Web of Science ®Google Scholar
• JudsonBAGoldsteinANaltrexone treatment of heroin addiction: one-year follow-upDrug Alcohol Depend19841343573656479015
   PubMed Web of Science ®Google Scholar
• MartinWRJasinskiDRManskyPANaltrexone, an antagonist for the treatment of heroin dependence. Effects in manArch Gen Psychiatry19732867847914707988
   PubMed Web of Science ®Google Scholar
• Modesto-LoweVVan KirkJClinical uses of naltrexone: a review of the evidenceExp Clin Psychopharmacol200210321322712233982
   PubMed Web of Science ®Google Scholar
• MinozziSAmatoLVecchiSDavoliMMaintenance agonist treatments for opiate dependent pregnant womenCochrane Database Syst Rev2008162CD00631818425946
   PubMed Web of Science ®Google Scholar
• (No Author)Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic AntagonistsArch Gen Psychiatry1978353335340365122
   PubMed Web of Science ®Google Scholar
• RounsavilleBJCan psychotherapy rescue naltrexone treatment of opioid addiction?NIDA Res Monogr199515037528742771
   PubMedGoogle Scholar
• HollisterLSchwinnRKasperPNaltrexone treatment of opiate-dependent personsDrug Alcohol Depend197723203209880876
   PubMed Web of Science ®Google Scholar
• DigiustoEShakeshaftARitterAO’BrienSMattickRPNEPOD Research GroupSerious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)Addiction200499445046015049745
   PubMed Web of Science ®Google Scholar
  Erratum inAddiction20051001139
   Google Scholar
• GibsonAEDegenhardtLJHallWDOpioid overdose deaths can occur in patients with naltrexone implantsMed J Aust2007186315215317309406
   PubMed Web of Science ®Google Scholar
• RitterAJNaltrexone in the treatment of heroin dependence: relationship with depression and risk of overdoseAust N Z J Psychiatry200236222422811982544
   PubMed Web of Science ®Google Scholar
• BrahenLSHendersonRKCaponeTKordalNNaltrexone treatment in a jail work-release programJ Clin Psychiatry1984459 Pt 249526469937
   PubMed Web of Science ®Google Scholar
• CornishJWMetzgerDWoodyGENaltrexone pharmacotherapy for opioid dependent federal probationersJ Subst Abuse Treat19971465295349437624
   PubMed Web of Science ®Google Scholar
• LingWWessonDRNaltrexone treatment for addicted health care professionals: a collaborative private practice experienceJ Clin Psychiatry1984459 Pt 246486469936
   PubMed Web of Science ®Google Scholar
• WashtonAMGoldMSPottashACSuccessful use of naltrexone in addicted physicians and business executivesAdv Alcohol Subst Abuse19844289966524509
   PubMedGoogle Scholar
• AntonREHoganIJalaliBRiordanCEKleberHDMultiple family therapy and naltrexone in the treatment of opiate dependenceDrug Alcohol Depend1981821571687318681
   PubMed Web of Science ®Google Scholar
• ResnickRBWashtonAMStone-WashtonNPsychotherapy and naltrexone in opioid dependenceNIDA Res Monogr1981341091156783917
   PubMedGoogle Scholar
• CarrollKMBallSANichCTargeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvementArch Gen Psychiatry200158875576111483141
   PubMed Web of Science ®Google Scholar
• PrestonKLSilvermanKUmbrichtADeJesusAMontoyaIDSchusterCRImprovement in naltrexone treatment compliance with contingency managementDrug Alcohol Depend199954212713510217552
   PubMed Web of Science ®Google Scholar
• ComerSDCollinsEDKleberHDNuwayserESKerriganJHFischmanMWDepot naltrexone: long-lasting antagonism of the effects of heroin in humansPsychopharmacology (Berl)2002159435136011823887
   PubMed Web of Science ®Google Scholar
• ComerSDSullivanMAWalkerEAComparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individualsJ Pharmacol Exp Ther200531531320133016144974
   PubMed Web of Science ®Google Scholar
• ComerSDSullivanMAYuEInjectable, sustained-release naltrexone for the treatment of opioid dependenceArch Gen Psychiatry200663221021816461865
   PubMed Web of Science ®Google Scholar
• HulseGKArnold-ReedDEO’NeilGChanCTHanssonRCAchieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implantsAddict Biol200491677215203441
   PubMed Web of Science ®Google Scholar
• HulseGKArnold-ReedDEO’NeilGChanCTHanssonRO’NeilPBlood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implantsAddict Biol200491596515203440
   PubMed Web of Science ®Google Scholar
• OlsenLChristophersenASFrogopsahlGWaalHMørlandJPlasma concentrations during naltrexone implant treatment of opiate-dependent patientsBr J Clin Pharmacol200458221922215255807
   PubMed Web of Science ®Google Scholar
• ColquhounRTanDYHullSA comparison of oral and implant naltrexone outcomes at 12 monthsJ Opioid Manag20051524925617319558
   PubMedGoogle Scholar
• CarreñoJEAlvarezCENarcisoGIBascaránMTDíazMBobesJMaintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependenceAddict Biol20038442943814690879
   PubMed Web of Science ®Google Scholar
• GarbuttJCKranzlerHRO’MalleySSEfficacy and tolerability of long-acting injectable naltrexone for alcohol dependenceJAMA20052931617162515811981
   PubMed Web of Science ®Google Scholar
• JohnsonBAAit-DaoudNAubinHJA pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependenceAlcohol Clin Exp Res20042891356136115365306
   PubMed Web of Science ®Google Scholar
• RoozenHGDeWaartRVanDenBrinkWEfficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable deliveryEur Addict Res200713420120617851241
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA)Drug Abuse Warning Network (DAWN), National Estimates of Drug-Related Emergency Department Visits, 2004–2009 Available from: http://dawninfo.samhsa.gov/data/ed/Nation/Nation_2009_Illicit.xlsAccesed 13 September, 2011
   Google Scholar
• PedapatiEBatemanSTToddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxonePediatr Crit Care Med2011122e102e10720921918
   PubMed Web of Science ®Google Scholar
• Suboxone Sublingual Film [package insert]Richmond, VAReckitt Benckiser Pharmaceuticals Inc2010
   Google Scholar
• CarrieriMPVlahovDDellamonicaPUse of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study GroupDrug Alcohol Depend2000601515410821989
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFSullivanLENallaniSDrug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a reviewAm J Addict200919141620132117
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse TreatmentClinical guidelines for the use of buprenorphine in the treatment of opioid addictionTreatment Improvement Protocol (TIP) Series 40 DHHS Publication No. (SMA) 04-3939Rockville, MDSubstance Abuse and Mental Health Services Administration2004 Available from: http://www.naabt.org/links/TIP_40_PDF.pdfAccessed Oct, 2011
   Google Scholar